Literature DB >> 21766391

Rapid identification of phase I and II metabolites of artemisinin antimalarials using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange technique.

Tian Liu1, Fuying Du, Yakun Wan, Fanping Zhu, Jie Xing.   

Abstract

Artemisinin drugs have become the first-line antimalarials in areas of multi-drug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of CYP-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoinduction of artemisinin drugs, we evaluated the biotransformation of artemisinin, also known as Qing-hao-su (QHS), and its active derivative dihydroartemisinin (DHA) in vitro and in vivo, using LTQ-Orbitrap hybrid mass spectrometer in conjunction with online hydrogen (H)/deuterium (D) exchange high-resolution (HR)-LC/MS (mass spectrometry) for rapid structural characterization. The LC separation was improved allowing the separation of QHS parent drugs and their metabolites from their diastereomers. Thirteen phase I metabolites of QHS have been identified in liver microsomal incubates, rat urine, bile and plasma, including six deoxyhydroxylated metabolites, five hydroxylated metabolites, one dihydroxylated metabolite and deoxyartemisinin. Twelve phase II metabolites of QHS were detected in rat bile, urine and plasma. DHA underwent similar metabolic pathways, and 13 phase I metabolites and 3 phase II metabolites were detected. Accurate mass data were obtained in both full-scan and MS/MS mode to support assignments of metabolite structures. Online H/D exchange LC-HR/MS experiments provided additional evidence in differentiating deoxydihydroxylated metabolites from mono-hydroxylated metabolites. The results showed that the main phase I metabolites of artemisinin drugs are hydroxylated and deoxyl products, and they will undergo subsequent phase II glucuronidation processes. This study also demonstrated the effectiveness of online H/D exchange LC-HR/MS(n) technique in rapid identification of drug metabolites.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766391     DOI: 10.1002/jms.1943

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  6 in total

1.  Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.

Authors:  Therese Ericsson; Antje Blank; Cornelia von Hagens; Michael Ashton; Angela Äbelö
Journal:  Eur J Clin Pharmacol       Date:  2014-09-25       Impact factor: 2.953

2.  Potent in vivo anti-malarial activity and representative snapshot pharmacokinetic evaluation of artemisinin-quinoline hybrids.

Authors:  Marli C Lombard; David D N'Da; Christophe Tran Van Ba; Sharon Wein; Jennifer Norman; Lubbe Wiesner; Henri Vial
Journal:  Malar J       Date:  2013-02-21       Impact factor: 2.979

3.  Oral Bioavailability Comparison of Artemisinin, Deoxyartemisinin, and 10-Deoxoartemisinin Based on Computer Simulations and Pharmacokinetics in Rats.

Authors:  Chunqing Fu; Henan Shi; Hong Chen; Keyu Zhang; Manyuan Wang; Feng Qiu
Journal:  ACS Omega       Date:  2020-12-28

4.  An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat.

Authors:  Fanping Zhu; Fuying Du; Xinxiu Li; Jie Xing
Journal:  Malar J       Date:  2012-11-21       Impact factor: 2.979

5.  A computational drug metabolite detection using the stable isotopic mass-shift filtering with high resolution mass spectrometry in pioglitazone and flurbiprofen.

Authors:  Masashi Uchida; Mitsuhiro Kanazawa; Atsushi Ogiwara; Hiroshi Sezaki; Akihiro Ando; Yohei Miyamoto
Journal:  Int J Mol Sci       Date:  2013-09-30       Impact factor: 5.923

6.  Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination.

Authors:  Meitong Zang; Fanping Zhu; Xinxiu Li; Aijuan Yang; Jie Xing
Journal:  Malar J       Date:  2014-06-03       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.